Primary Site >> Esophagus Cancer
Gene >> CD274
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. PMID: 15837746 |
Ref: T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. PMID: 21717068 |
Ref: B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. PMID: 25337246 |
Ref: PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PMID: 26114883 Ref: The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. PMID: 26451118 Ref: Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. PMID: 26487950 |
Ref: The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. PMID: 26761210 Ref: Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. PMID: 27015293 Ref: PD-L1 expression in human cancers and its association with clinical outcomes. PMID: 27574444 Ref: The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. PMID: 27854242 |
Ref: Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. PMID: 27470134 Ref: Basis for molecular diagnostics and immunotherapy for esophageal cancer. PMID: 27838937 Ref: Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. PMID: 28271259 Ref: PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. PMID: 28314315 Ref: Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. PMID: 28359471 Ref: Promising immunotherapies for esophageal cancer. PMID: 28366014 Ref: Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. PMID: 28657901 Ref: MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. PMID: 28693258 Ref: The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. PMID: 28806299 Ref: PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. PMID: 28848143 Ref: [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review]. PMID: 29050127 Ref: PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. PMID: 29206673 Ref: [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors]. PMID: 29239193 Ref: [Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies]. PMID: 29488776 |
Ref: Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. PMID: 29358502 Ref: Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. PMID: 29552135 Ref: Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. PMID: 29805749 Ref: Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer. PMID: 29859152 Ref: Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature. PMID: 30045299 Ref: Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. PMID: 30174892 Ref: What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies? PMID: 30231398 Ref: Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. PMID: 30275174 |